Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Common analytical approaches include reversed-phase high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Peptide mapping after enzymatic digestion can verify the expected sequence. Immunoassays may be used to measure the compound or its downstream markers, but they can cross-react with related peptides and require careful validation. Impurity profiles typically include truncated sequences, oxidized methionine residues, and residual solvents from synthesis. Each method reports a different property, so no single assay establishes overall quality.
Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Requires reconstitution before use |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Storage, powder | 2 to 8 degrees Celsius | Protect from light and moisture |
| Storage, solution | Refrigerated, short term | Use promptly after reconstitution |
| Common assays | Reversed-phase HPLC and mass spectrometry | Purity and identity respectively |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
The two substrates of this enzyme are myo-inositol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 2,4,6/3,5-pentahydroxycyclohexanone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is myo-inositol:NAD+ 2-oxidoreductase. Other names in common use include myo-inositol 2-dehydrogenase, myo-inositol:NAD+ oxidoreductase, inositol dehydrogenase, and myo-inositol dehydrogenase. This enzyme participates in inositol metabolism and inositol phosphate metabolism.
Bradykinin is rapidly inactivated in the circulating blood, and it disappears completely in a single pass through the pulmonary circulation. Angiotensin I also disappears in the pulmonary circulation because of its conversion to angiotensin II. Furthermore, angiotensin II passes through the lungs without any loss. The inactivation of bradykinin and the conversion of angiotensin I to angiotensin II in the lungs was thought to be caused by the same enzyme. In 1970, Ng and Vane, using BPF provided by Ferreira, showed the conversion is inhibited during its passage through the pulmonary circulation. BPFs are members of a family of peptides whose potentiating action is linked to inhibition of bradykinin by ACE. Molecular analysis of BPF yielded a nonapeptide BPF teprotide (SQ 20,881), which showed the greatest ACE inhibition potency and hypotensive effect in vivo. Teprotide had limited clinical value as a result of its peptide nature and lack of activity when given orally. In the early 1970s, knowledge of the structure-activity relationship required for inhibition of ACE was growing. David Cushman, Miguel Ondetti and colleagues used peptide analogs to study the structure of ACE, using carboxypeptidase A as a model. Their discoveries led to the development of captopril, the first orally-active ACE inhibitor, in 1975. Captopril was approved by the United States Food and Drug Administration in 1981. The first nonsulfhydryl-containing ACE inhibitor, enalapril, was approved four years later. At least 8 other ACE inhibitors have since been marketed.
The coat of arms of Scarborough was adopted when the borough became a city on June 29, 1983. A grant of arms was issued by the Canadian Heraldic Authority on February 1, 1996. The coat of arms had a shield within a laurel wreath. Upon this shield were the following elements, in quarters:
March 12: Law expanding the civil capacity of professional unions; married women may join and participate (including in administration and leadership) without their husband's permission. July 31: Law criminalizing incitement to abortion and anti-contraceptive propaganda. August 12: Decree enacting the Peace Treaty of November 27, 1919, which created the League of Nations (SDN) and established principles such as the prohibition of child labor, restrictions on youth labor for both sexes, and "equal pay for equal work"; women may be technical advisors within the SDN on certain topics. 1921
=== Environment === Deforestation in the Brazilian Amazon rainforest fell 61% in January 2023 from a year earlier following a series of anti-logging and anti-mining operations launched by government agencies under Lula, according to satellite data. In June 2023, the Environment Ministry announced a plan to curb deforestation in Brazil's Legal Amazon, and immediately embargoed all activities being developed inside conservation parks in the region. Additionally, the government announced the creation of 3 million hectares (7,413,161.44 acres) in protected areas until 2027/ the creation of tracking system using geopositioning for Amazon agricultural products and ecolabels were announced as well. In July 2023, deforestation in the Brazilian Amazon was reported to have fallen 34% over the previous six months while deforestation in the Brazilian Atlantic forest dropped 42% from January to May 2023 comparatively to the same period of time in 2022. In November 2023, Brazil's National Institute for Space Research (INPE) reported that the Amazon deforestation rate fell 22% between August 2022 and July 2023, compared to its previous 2021–2022 report (during Jair Bolsonaro's presidency). Considering only the period of the Lula government, the drop is accentuated to 49.7% compared to the same period of the previous year. Deforestation in protected areas fell the most, being the lowest in 9 years. In total, Imazon highlighted that 2023 had the lowest deforestation rate since 2017.
Sources: en.wikipedia.org
acylation, e.g. O-acylation (esters), N-acylation (amides), S-acylation (thioesters) acetylation, the addition of an acetyl group, either at the N-terminus of the protein or at lysine residues. The reverse is called deacetylation. formylation alkylation, the addition of an alkyl group, e.g. methyl, ethyl methylation the addition of a methyl group, usually at lysine or arginine residues. The reverse is called demethylation. amidation at C-terminus. Formed by oxidative dissociation of a C-terminal Gly residue. monoaminylation, addition of monoamines to glutamine residues via transamidation dopaminylation, the addition of dopamine to glutamine residues via transamidation histaminylation, the addition of histamine to glutamine residues via transamidation serotonylation, the addition of serotonin to glutamine residues via transamidation amide bond formation amino acid addition arginylation, a tRNA-mediation addition polyglutamylation, covalent linkage of glutamic acid residues to the N-terminus of tubulin and some other proteins. (See tubulin polyglutamylase) polyglycylation, covalent linkage of one to more than 40 glycine residues to the tubulin C-terminal tail butyrylation gamma-carboxylation dependent on Vitamin K glycosylation, the addition of a glycosyl group to either arginine, asparagine, cysteine, hydroxylysine, serine, threonine, tyrosine, or tryptophan resulting in a glycoprotein. Distinct from glycation, which is regarded as a nonenzymatic attachment of sugars.
If a crystal has three axes at right angles to each other then, if they are equivalent, the crystal is isotropic, if two are equivalent and the third different, the crystal is uniaxial, and if all three are different, the crystal is biaxial. In 1822 John Herschel proposed a causal relationship between the handedness of quartz crystals (right- or left-handed) and the direction of their optical rotation. In 1840 Friedrich Ludwig Hünefeld described the first crystallization of a protein; Hünefeld obtained lamellar crystals (later identified as haemoglobin) by putting the blood of an earthworm between two slides.
=== 26 February === According to a Russian source, border clashes between Belarus and Ukraine resulted in the death of one Belarusian soldier. A Russian Beriev A-50U plane at the Machulishchy air base was said to have been destroyed by Belarusian partisans. However, satellite imagery of the Machulishchy air base from 28 February showed the sole A-50 located there still largely intact.
The public entity was called Fisher Scientific International Inc., and based in Hampton, New Hampshire. Fisher Scientific Company remained in Pittsburgh as an operating subsidiary. In 1992, Fisher facilities were ISO-9000 certified. In the 1990s, Fisher, with partner Intertech Corporation of Atkinson, New Hampshire, set up a pharmaceutical testing and certification lab in Moscow, Russia, to serve with the Russian Federation's Ministry of Health and Medical Industry needs. Fisher acquired Eastman Kodak Company's organic-chemicals business and Janssen Chimica, forming Acros Organics. In August 2004, the company merged with Apogent Technologies Inc., a company engaged primarily in the manufacture and sale of laboratory products in the United States and other countries. In May 2006, Fisher Scientific and Thermo Electron announced that they would merge in a tax-free, stock-for-stock exchange. The merger closed on November 9, 2006, and the merged company is now called Thermo Fisher Scientific. The merger was valued at $12.8 billion.
Beta-peptides (β-peptides) are peptides derived from β-amino acids, in which the amino group is attached to the β-carbon (i.e. the carbon two atoms away from the carboxylate group). The parent β-amino acid is β-alanine (H2NCH2CH2CO2H), a common natural substance, but most examples feature substituents in place of one or more C-H bonds. β-peptides usually do not occur in nature. β-Peptide-based antibiotics are being explored as ways of evading antibiotic resistance. Early studies in this field were published in 1996 by the group of Dieter Seebach and that of Samuel Gellman.
Sources: en.wikipedia.org
=== Structure === Scaffolds are used in tissue engineering to create an environment with similar mechanical properties of the native tissue. Scaffolds must be biocompatible and have high compressive strength. Scaffolds can be created from hydrogels, polymers or other material. Hydrogels are lightly cross-linked polymer networks swollen with water. Degree of crosslinking, porosity, and polymer composition can be tuned to create a hydrogel with similar properties to native cartilage. Researchers have been exploring the use of hydrogels as a cartilage substitute since the 1970s.
Chitin is the world's second most abundant natural polymer, with collagen being the first. It is a "linear polysaccharide of β-(1-4)-2-acetamido-2-deoxy-D-glucose". Chitin is highly crystalline and is usually composed of chains organized into β sheet. Due to its high crystallinity and chemical structure, it is insoluble in many solvents. It also has low toxicity in the human body and is inert in the intestines. Chitin also has antibacterial properties. Chitin forms crystals that make fibrils that become surrounded by proteins. These fibrils can bundle to form larger fibers that contribute to the hierarchical structure of many biological materials. These fibrils can form randomly oriented networks that provide the mechanical strength of the organic layer in different biological materials. Chitin provides protection and structural support to many living organisms. It makes up the cell walls of fungi and yeast, the shells of mollusks, the exoskeletons of insects and arthropods. In shells and exoskeletons, the chitin fibers contribute to their hierarchical structure. In nature, pure chitin (100% acetylation) does not exist. It instead exists as a copolymer with chitin's deacetylated derivative, chitosan. When the acetylized composition of the copolymer is over 50% acetylated it is chitin. This copolymer of chitin and chitosan is a random or block copolymer.
=== Cardiac-valvular === Cardiac-valvular EDS (cvEDS) is characterized by three major criteria: severe progressive cardiac-valvular problems (affecting aortic and mitral valves), skin problems such as hyperextensibility, atrophic scarring, thin skin, and easy bruising, and joint hypermobility (generalized or restricted to small joints). Four minor criteria may aid in the diagnosis of cvEDS. cvEDS is an autosomal recessive disorder, inherited through variation in both alleles of the gene COL1A2.
The next doubly magic nucleus is now expected to be around 306Ubb, but this nuclide's expected short half-life and low production cross section make its synthesis challenging. Still, the island of stability is expected to exist in this region, and nearer its centre (which has not been approached closely enough yet) some nuclides, such as 291Mc and its alpha- and beta-decay daughters, may be found to decay by positron emission or electron capture and thus move into the centre of the island. Due to the expected high fission barriers, any nucleus in this island of stability would decay exclusively by alpha decay and perhaps some electron capture and beta decay, both of which would bring the nuclei closer to the beta-stability line where the island is expected to be. Electron capture is needed to reach the island, which is problematic because it is not certain that electron capture is a major decay mode in this region of the chart of nuclides. Experiments were done in 2000–2004 at Flerov Laboratory of Nuclear Reactions in Dubna studying the fission properties of the compound nucleus 292Fl by bombarding 244Pu with accelerated 48Ca ions. A compound nucleus is a loose combination of nucleons that have not yet arranged themselves into nuclear shells. It has no internal structure and is held together only by the collision forces between the two nuclei. Results showed how such nuclei fission mainly by expelling doubly magic or nearly doubly magic fragments such as 40Ca, 132Sn, 208Pb, or 209Bi.
On 12 June 2025, the International Atomic Energy Agency (IAEA) found Iran non-compliant with its NPT safeguards agreement for the first time since 2005. A few days later, it was reported that Iran had stored highly enriched uranium in an underground facility that was undamaged by US bombings in 2025. Subsequently, Iran denied the IAEA access to nuclear facilities that had been bombed, but did provide access to all unaffected facilities. Mohammad Eslami, the head of the Atomic Energy Organization of Iran, said Iran would not permit inspections of facilities struck by the US until the IAEA established rules for the post-war situation, insisting on codified protocols for internationally protected facilities subjected to military attacks, and that the IAEA condemn the attacks. In February 2026, Iran informed the IAEA that normal safeguards were "legally untenable and materially impracticable" as a result of threats and "acts of aggression", leaving the IAEA unable to verify that Iran had suspended enrichment or confirm the status of its stockpile, though it found no evidence Iran was weaponizing. Analysts in the UK and US characterized Iran's strategy as nuclear hedging. The Bulletin of the Atomic Scientists said that Iran was using its enrichment program and uranium stockpiles for leverage in international negotiations, and was willing to dilute or export its higher-level enriched uranium in exchange for sanctions relief and prevention of attacks.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius with protection from light is the common recommendation. Many laboratories choose frozen storage at minus 20 degrees Celsius when the material will not be used soon. Repeated temperature cycling is generally avoided.
Mass spectrometry gives the observed mass, which is compared against the value calculated from the sequence. Peptide mapping after digestion provides a second, sequence-level check. Chromatographic retention alone is not sufficient for identity.
Antibodies raised against one GHRH-related peptide may bind other members of the same family. That cross-reactivity inflates or distorts measured concentrations. Assay validation with defined standards is therefore necessary before results are interpreted.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.